Pure Global
NCT06289894

A Study of BRY805 in Participants With Advanced Solid Tumors

A Phase I, Open-label, Single Arm Study to Evaluate the Safety, Tolerability, and Antitumor Activity of BRY805 in Participants With Advanced Solid Tumors
BioRay Pharmaceutical Co., Ltd.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
BRY805 injection
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
BioRay Pharmaceutical Co., Ltd.
Location
Jinan, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 01, 2024
End date
Sep 01, 2027
Enrollment
30 participants
Primary outcome

Occurrence of Drug Limited Toxicities (DLTs),Type and incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)

Summary

This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum
 tolerance of BRY805 administered intravenously (IV) once every three weeks in participants
 with advanced solid tumors, so as to confirm the recommended phase 2 dose of BRY805 and
 obtain the preliminary efficacy information of participants with advanced solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06289894
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06289894 through Pure Global AI's free database. This Phase 1 trial is sponsored by BioRay Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.